Continuing Education Company 30th Annual Hypertension, Diabetes, & Dyslipidemia Conference 2026
Advanced Updates in Cardiometabolic Disease Management for Primary Care and Specialty Practice
The 30th Annual Hypertension, Diabetes, & Dyslipidemia Conference 2026 is a comprehensive educational program designed to provide healthcare professionals with the latest evidence-based strategies for managing three of the most common and impactful chronic diseases encountered in clinical practice: hypertension, diabetes, and dyslipidemia. Held in Savannah, Georgia, from June 3–5, 2026, this conference delivers practical clinical updates focused on improving cardiovascular outcomes, reducing long-term complications, and optimizing patient-centered care.
Developed by Continuing Education Company, this long-standing conference combines current clinical guidelines, emerging therapies, risk reduction strategies, and individualized treatment approaches for patients with cardiometabolic disorders.
Course Overview
Hypertension, diabetes, and dyslipidemia remain leading contributors to cardiovascular disease, stroke, chronic kidney disease, and premature mortality worldwide. As treatment options continue to evolve and new evidence emerges, clinicians must stay current with modern approaches to risk assessment, diagnosis, monitoring, and management.
This conference provides a focused review of contemporary clinical practices, emphasizing guideline-based care, individualized treatment plans, and practical interventions that can be immediately implemented in outpatient and primary care settings.
Participants will gain valuable insights into managing complex patients with multiple cardiometabolic risk factors while learning strategies to improve long-term health outcomes.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Formulate effective assessment and monitoring plans for patients with hypertension, diabetes, and dyslipidemia.
- Apply current clinical guidelines in the diagnosis and treatment of cardiometabolic disorders.
- Develop individualized treatment strategies based on patient-specific risk profiles.
- Implement evidence-based interventions to improve blood pressure control.
- Optimize diabetes management using current therapeutic approaches.
- Evaluate and manage lipid disorders to reduce cardiovascular risk.
- Improve long-term patient outcomes through comprehensive risk-factor modification.
- Incorporate lifestyle medicine principles into chronic disease management.
- Recognize and manage common comorbidities associated with cardiometabolic disease.
Key Topics Covered
Hypertension Management
Participants review:
- Current hypertension guidelines
- Blood pressure targets
- Risk stratification
- Resistant hypertension
- Secondary hypertension evaluation
- Pharmacologic treatment strategies
- Lifestyle interventions
Special emphasis is placed on cardiovascular risk reduction and individualized treatment planning.
Diabetes Management
Topics include:
- Type 2 diabetes diagnosis
- Glycemic control strategies
- Evidence-based treatment algorithms
- Cardiovascular risk management
- Diabetes complications prevention
- Continuous glucose monitoring
- Emerging diabetes therapies
Faculty provide practical approaches to optimizing outcomes while minimizing treatment-related risks.
Dyslipidemia & Lipid Management
Coverage includes:
- Lipid screening recommendations
- ASCVD risk assessment
- Statin therapy updates
- Hypertriglyceridemia management
- LDL cholesterol reduction strategies
- Novel lipid-lowering therapies
- Prevention of cardiovascular events
Participants learn how to apply current cholesterol guidelines in daily practice.
Cardiometabolic Risk Reduction
Sessions focus on:
- Integrated management of hypertension, diabetes, and dyslipidemia
- Prevention of cardiovascular disease
- Obesity and metabolic syndrome
- Lifestyle modification strategies
- Nutrition counseling
- Exercise recommendations
- Smoking cessation
Clinicians gain practical tools for comprehensive cardiovascular prevention.
Individualized Treatment Strategies
Topics include:
- Personalized medicine approaches
- Risk-based treatment decisions
- Shared decision-making
- Management of complex patients
- Multimorbidity considerations
- Long-term monitoring plans
The program emphasizes tailoring therapy to each patient’s unique clinical profile.
Educational Features
✔ Evidence-Based Clinical Updates
✔ Current Guideline Reviews
✔ Practical Outpatient Management Strategies
✔ Cardiovascular Risk Reduction Focus
✔ Personalized Treatment Approaches
✔ Case-Based Learning
✔ Expert Faculty Presentations
✔ Immediate Clinical Application
Target Audience
This course is ideal for:
- Family Medicine Physicians
- General Practice Physicians
- Internal Medicine Physicians
- Endocrinologists
- Geriatricians
- Lipidologists
- Hypertension Specialists
- Primary Care Physicians
- Nurse Practitioners
- Physician Assistants
- Healthcare Professionals Managing Cardiometabolic Disease
Why This Course Stands Out
✔ Focused exclusively on hypertension, diabetes, and dyslipidemia
✔ Covers the latest evidence-based guidelines and therapies
✔ Emphasizes practical management strategies for everyday practice
✔ Strong cardiovascular prevention focus
✔ Addresses multiple interconnected cardiometabolic disorders
✔ Applicable to both primary care and specialty practice
✔ Designed to improve patient outcomes and reduce complications
✔ Led by experienced experts in chronic disease management
Clinical Value
The Continuing Education Company 30th Annual Hypertension, Diabetes, & Dyslipidemia Conference 2026 provides a comprehensive review of modern cardiometabolic medicine. Covering hypertension, diabetes, lipid disorders, cardiovascular prevention, risk assessment, and personalized treatment strategies, this course equips clinicians with the knowledge and tools necessary to improve patient care and achieve better long-term health outcomes.
+ Topics:
*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below
WEDNESDAY, June 3, 2026
| Day 1: Focus on Diabetes | ||
| 7:50 am – 8:00 am | Welcome | A. Mullins, CHCP & J. Basile, MD |
| 8:00 am – 8:45 am | Standards of Care in Type 2 Diabetes in 2026 | C. Low Wang, MD |
| 8:45 am – 9:30 am | Diabetes and Metabolic Associated Steatotic Liver Disease (MASLD)-Evaluation and Treatment | C. Wysham, MD |
| 9:30 am – 10:15 am | Navigating GLP-1RA and SGLT2i Use in Your Patients with Diabetes and Obesity | C. Low Wang, MD |
| 10:15 am: BREAK | ||
| 10:30 am – 11:15 am | Weight Management in Those with Diabesity or Atypical Forms of Diabetes in the Adult | C. Wysham, MD |
| 11:15 am – 11:30 am | Questions for the Faculty | C. Low Wang, MD & C. Wysham, MD |
| 11:30 am – 12:45 pm | Cases from the Faculty | C. Low Wang, MD & C. Wysham, MD |
THURSDAY, June 4, 2026
| Day 2: Focus on Hypertension | ||
| 7:40 am – 7:45 am | Welcome | A. Mullins, CHCP |
| 7:45 am – 8:00 am | Day One Review of Key Points | J. Basile, MD |
| 8:00 am – 9:00 am | What’s New in Outpatient Hypertension: Clinical Pearls from the New 2025 HTN Guideline | J. Basile, MD |
| 9:00 am – 9:45 am | MRA’s (Steroidal and Non-Steroidal) and Aldosterone Synthase Inhibitors in Hypertension and Renal Disease | G. Hundemer, MD |
| 9:45 am – 10:30 am | Hypertension in Older Women; Illuminating a Bright Spot | B. Egan, MD |
| 10:30 am: BREAK | ||
| 10:45 am – 11:30 am | Rethinking Primary Aldosteronism | G. Hundemer, MD |
| 11:30 am – 12:15 pm | Reframing Goal BP to Align Patients and Providers on the Target | B. Egan, MD |
| 12:15 pm – 12:30 pm | Questions for the Faculty | J. Basile, MD, G. Hundemer, MD, & B. Egan, MD |
| 12:30 pm: LUNCH BREAK (Working Lunch) | ||
| 12:45 pm – 2:15 pm | Cases in Hypertension | K. Bryant, MD and above faculty |
FRIDAY, June 5, 2026
| Day 3: Focus on Dyslipidemia | ||
| 7:40 am – 7:45 am | Welcome | A. Mullins, CHCP |
| 7:45 am – 8:00 am | Day Two Review of Key Points | J. Basile, MD |
| 8:00 am – 8:45 am | What’s New in the ACC/AHA Cholesterol Guidelines? | M. Blaha, MD |
| 8:45 am – 9:30 am | Applying the 2026 ACC/AHA Cholesterol Guidelines in Practice | R. Dudum, MD |
| 9:30 am – 10:15 am | What’s on the HORIZON with Lp(a): Comparing the Nearly Completed Lp(a) Trials | M. Blaha, MD |
| 10:15 am: BREAK | ||
| 10:30 am – 11:15 am | Making Sense of Non-Statin Lipid-Lowering Therapies: The When and Why to Use Them | R. Dudum, MD |
| 11:15 am – 11:30 am | Questions for the Faculty | M. Blaha, MD & R. Dudum, MD |
| 11:30 am – 12:45 pm | Cases in Lipids | M. Blaha, MD & R. Dudum, MD |








